Neogen Corp. (NEOG) Stock
Key stats
- Market cap
- $2.53B
- Price / Earnings ratio
- -45.4x
- EPS (TTM)
- -$0.26
- Volume
- Loading
- 52-week high
- $14.26
- 52-week low
- $5.37
- EPS vs analyst estimate
- +33.3%Q1 FY26 · $0.04 vs $0.03
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with NEOG
Recent news

Neogen® To Participate in 2026 UBS Global Healthcare Conference
Neogen® To Participate in 2026 UBS Global Healthcare Conference
NEOG

NEOG vs. WFCF: Which Food Safety Stock Has Better Prospects?
NEOG vs. WFCF: Which Food Safety Stock Has Better Prospects?
NEOG

3 Medical Product Stocks Positioned to Ride on the Industry Tailwinds
3 Medical Product Stocks Positioned to Ride on the Industry Tailwinds
NEOG

Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031
Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031
NEOG
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 44.04
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.03
- SMA 50
- $12.26
- Price below SMA 50
- EMA 50
- $11.95
- Price below EMA 50
- SMA 200
- $10.51
- Price above SMA 200
- EMA 200
- $10.44
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
The market is expecting earnings per share of $0.08 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Neogen® To Participate in 2026 UBS Global Healthcare Conference
Neogen® To Participate in 2026 UBS Global Healthcare Conference
NEOG

NEOG vs. WFCF: Which Food Safety Stock Has Better Prospects?
NEOG vs. WFCF: Which Food Safety Stock Has Better Prospects?
NEOG

3 Medical Product Stocks Positioned to Ride on the Industry Tailwinds
3 Medical Product Stocks Positioned to Ride on the Industry Tailwinds
NEOG

Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031
Neogen Investor Day Sets Path for Growth, 30% EBITDA Margin by 2031
NEOG

Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day
Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day
NEOG

Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics
NEOG

What Neogen (NEOG) Said on Its Q1 Earnings Call
What Neogen (NEOG) Said on Its Q1 Earnings Call
NEOG

Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates
NEOG

Neogen Reports First-Quarter Financial Results for Fiscal Year 2027
Neogen Reports First-Quarter Financial Results for Fiscal Year 2027
NEOG

Neogen Announces Strategic Collaboration with Hinalea Imaging to Advance Digital Food Safety Solutions
Neogen Announces Strategic Collaboration with Hinalea Imaging to Advance Digital Food Safety Solutions
NEOG
News tone: automated (AI) classification of the article's content, not a price prediction.
About Neogen Corp.
NEOGEN Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns. NEOGEN's Animal Safety Division is a leader in the development of animal genomics along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care and disinfectants.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mikhael Nassif | CEO, President & Director | 1976 |
| Mr. R. Bryan Riggsbee CPA | CFO & Senior Vice President | 1970 |
| Ms. Jennifer Evans Stacey Esq., J.D. | Senior VP, Chief Legal & Compliance Officer and Board Secretary | 1965 |
| Dr. Tamara A. Ranalli Ph.D. | Senior VP & GM of Global Food Safety | 1973 |
| Mr. John Moylan | VP, Corporate Controller & Chief Accounting Officer | — |
| Dr. Jeremy Yarwood | Chief Scientific Officer | — |
| Sarah Demey | Administrative Manager | — |
| Mr. Kevin M. Burke | Chief Human Resources Officer | 1969 |
| Mr. Joe Freels | Senior VP & Chief Commercial Officer | — |
| Mr. Jim Walter | Senior Vice President of Manufacturing & Operations | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.04
- MACD 12/26/9
- -0.11
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.03
- SMA 50
- $12.26
- Price below SMA 50
- EMA 50
- $11.95
- Price below EMA 50
- SMA 200
- $10.51
- Price above SMA 200
- EMA 200
- $10.44
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.00
- Average
- $14.00
- High
- $14.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.0 | +15.4 | ||||||||||
| 2022 | -17.8 | -2.1 | -13.5 | -16.2 | -0.7 | -8.4 | -4.8 | -7.4 | -26.5 | -5.2 | +23.9 | -7.7 |
| 2023 | +40.3 | -15.2 | +0.9 | -2.5 | +1.2 | +17.4 | +7.6 | +2.4 | -20.5 | -15.7 | +14.9 | +15.3 |
| 2024 | -23.8 | +12.4 | -8.2 | -18.2 | +7.3 | +13.9 | +13.2 | +1.5 | +4.4 | -8.5 | -1.8 | -11.8 |
| 2025 | -4.0 | -8.1 | -7.9 | -39.8 | +13.8 | -16.0 | -8.5 | +23.4 | +1.2 | +6.4 | -4.9 | +18.1 |
| 2026 | +46.0 | +9.6 | -16.7 | +0.1 | -5.9 | +0.8 | +29.3 | -2.9 | +10.0 | -3.4 | -1.9 |



